Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis

NCT02413229 is registered in ClinicalTrials.gov with Sun Pharmaceutical Industries, Inc. as lead sponsor.

NCT NCT02413229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02413229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
January 29, 2016
Enrollment
151 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis